Recent Progress and Challenges Regarding Magnetite-Based Nanoparticles for Targeted Drug Delivery

Abstract

Magnetite-based nanoparticles are of constant interest in the scientific community as potential systems for biomedical applications. Over the years, the ability to synthesize diverse systems based on iron (II, III) oxide nanoparticles has been mastered to maximize their potential effectiveness in the targeted delivery of active substances in cancer therapy. The present review explores recent literature findings that detail various magnetic nanosystems. These encompass straightforward designs featuring a polymer coating on the magnetic core and more intricate matrices for delivering chemotherapeutic drugs. This paper emphasizes novel synthetic approaches that impact the efficacy and progress of anticancer investigations, specifically targeting a particular cancer type. The research also delves into combinations with alternative treatment methods and diagnostic approaches. Additionally, it highlights a critical aspect—the interaction with cells—identifying it as the least developed aspect in current research on these systems.

Shape Matters: Impact of Mesoporous Silica Nanoparticle Morphology on Anti-Tumor Efficacy

“…This can help maximize the drug concentration within tumor tissues while minimizing impacts on the surrounding normal tissues [5,6], and nano-carriers can effectively enhance the water solubility of drugs and slow down drug metabolism, thereby prolonging the circulation time of drugs in the body [7,8]. Furthermore, nanotechnologies such as molecularly imprinted polymers (MIPs) with diagnostic and targeted therapeutic capabilities; transdermal nanotechnology for skin cancer; lanthanidebased nanoparticles coated with specific peptides, ligands, and proteins targeting the tumor microenvironment; as well as magnetite nanoparticles for targeted drug delivery all show promising development [9][10][11][12]. These nanotechnologies provide drugs with a longer-lasting therapeutic effect, offering patients with breast cancer more sustainable treatment outcomes.…”